Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tirumotecan”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06170788
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 614
Testing effectiveness (Phase 2)Looking for participantsNCT07256236
What this trial is testing

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
Fujian Cancer Hospital 89
Large-scale testing (Phase 3)Active Not RecruitingNCT06132958
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 710
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07819578
What this trial is testing

Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shaodong Hong 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750704
What this trial is testing

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 153
Testing effectiveness (Phase 2)Looking for participantsNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT07323056
What this trial is testing

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China 36
Testing effectiveness (Phase 2)Looking for participantsNCT07697586
What this trial is testing

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 206
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07054242
What this trial is testing

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Neoadjuvant TherapyStage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701122
What this trial is testing

Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer

Who this might be right for
Advanced Biliary Tract Cancer(BTC)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07804966
What this trial is testing

Sac-TMT in Vaginal and Vulvar Cancers

Who this might be right for
Vaginal Squamous Cell CarcinomaVulvar Squamous Cell Carcinoma
Latin American Cooperative Oncology Group 48
Early research (Phase 1)Active Not RecruitingNCT06049212
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Who this might be right for
Non-small Cell Lung CancerSolid TumorsProgrammed Cell Death-1 (PD1, PD-1)+2 more
Merck Sharp & Dohme LLC 30
Testing effectiveness (Phase 2)Looking for participantsNCT07438626
What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for
Phase IISacituzumabTirumotecan+1 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701681
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
ESCCGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+2 more
Sun Yat-sen University 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128693
What this trial is testing

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 60
Large-scale testing (Phase 3)Looking for participantsNCT06312137
What this trial is testing

Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Who this might be right for
Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC 780
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07139470
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 59
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07458113
What this trial is testing

Sac-TMT for Active TNBC Brain Metastases

Who this might be right for
Metastatic Triple Negative Breast Cancers
Yale University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07623577
What this trial is testing

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Who this might be right for
TNBCBrain Metastasis
Fudan University 24
Next Page